2LBA Denosumab versus zoledronic acid for the treatment of breast cancer patients with bone metastases: results of a randomized phase 3 studyAlison Stopeck, Guenther G. Steger, Roger Dansey et al.|European Journal of Cancer Supplements|2009Cited by 84